Nasdaq
$2.33▲ 0.22%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $648.4MShares out 2.800M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.6After-hours26.10.07 05:424Ownership#●●●
Sana Biotechnology, Inc.
Sana Biotechnology executive Bishop Hans Edgar reported a change in beneficial ownership of securities as of October 5, 2026. This filing serves as a standard disclosure of insider equity transactions and does not indicate any material changes to the company's financial status or operations.…more
$2.33+0.22%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.8Pre-market26.09.08 21:008-KKey event
Sana Biotechnology, Inc.
Sana Biotechnology released an updated corporate presentation on September 8, 2026, reaffirming its goal to file an IND and initiate a Phase 1/2 trial for its Type 1 diabetes candidate, SC451, within this year. The company also highlighted technical progress and non-clinical data for its next-generation in vivo CAR T programs, SG293 and SG227.…more
$2.33+0.22%vs prev closeView filingShare - 8.27After-hours26.08.28 05:214Ownership
Sana Biotechnology, Inc.
Dhavalkumar Dhirajlal Patel, an insider at Sana Biotechnology, filed a Form 4 with the SEC on August 27, 2026, reporting a change in beneficial ownership of securities as of August 26, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$2.33+0.22%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.1After-hours26.09.02 05:05#●●●#●●●
Sana Biotechnology to Present at September Investor Conferences
Sana Biotechnology announced it will participate in four investor conferences throughout September to provide business overviews and updates. As these presentations are standard corporate updates rather than major clinical or financial catalysts, the impact on the stock is expected to be neutral.…more
$2.33+0.22%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.10After-hours26.08.11 05:05
●●●●●●●● ●●●●● ●●●●●●
사나 바이오테크놀로지는 주요 파이프라인인 SC451과 SG293의 임상 진입을 위한 준비가 순조롭게 진행 중이라고 밝혔습니다. 메이요 클리닉과의 전략적 협업 및 지분 투자를 통해 연구 개발 자금을 확보하며 내년 중반까지의 운영 자금을 마련했습니다.…more
$2.33+0.22%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report